Summary
Cardinal Health Inc. reported strong revenue growth in the third quarter of fiscal year 2026, with a 11% increase to $60.9 billion for the quarter and a 17% increase to $190.6 billion for the nine-month period. This growth was primarily driven by strong performance in branded and specialty pharmaceutical sales. While GAAP operating earnings saw a decrease of 30% to $509 million for the quarter, largely due to a significant goodwill impairment charge related to the Navista & ION reporting unit, non-GAAP operating earnings increased by 18% to $956 million. This highlights the company's underlying operational strength excluding one-time charges. Despite the GAAP earnings dip, the company demonstrated robust non-GAAP diluted EPS growth of 35% to $3.17 for the quarter and 36% to $8.35 for the nine-month period. Significant strategic acquisitions, including Solaris Health, Advanced Diabetes Supply Group, and GI Alliance, are contributing positively to revenue and profit growth, particularly within the Pharmaceutical and Specialty Solutions segment. The company's liquidity remains strong, with $3.9 billion in cash and equivalents and access to substantial credit facilities.
Key Highlights
- 1Consolidated revenue surged by 11% to $60.9 billion for the third quarter of fiscal 2026, driven by strong performance in the Pharmaceutical and Specialty Solutions segment.
- 2Non-GAAP operating earnings increased by 18% to $956 million for the quarter, showcasing underlying business growth despite a 30% decrease in GAAP operating earnings ($509 million), which was impacted by a $184 million goodwill impairment charge.
- 3Non-GAAP diluted EPS demonstrated substantial growth, rising 35% to $3.17 for the quarter and 36% to $8.35 for the nine-month period.
- 4The Pharmaceutical and Specialty Solutions segment saw revenue increase by 11% to $56.1 billion for the quarter, with segment profit growing 18% to $784 million, boosted by acquisitions and generics program performance.
- 5Strategic acquisitions, including Solaris Health, Advanced Diabetes Supply Group, and GI Alliance, are positively contributing to the company's financial results.
- 6The company maintained a strong liquidity position with $3.9 billion in cash and equivalents and compliance with its net leverage ratio covenant.
- 7Increased interest expense, particularly for the nine-month period (up 91% to $269 million), is noted, primarily due to additional debt financing for recent acquisitions.